Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer

Journal of Chemotherapy

Volumn 28, Issue 3, 2016, Pages 218-224

  Fu, Yan ^a   Hu, Jia ^a   Du, Nan ^a   Jiao, Shunchang ^a   Li, Fang ^a   Li, Xiaosong ^a   Ma, Junxun ^a   Zhao, Hui ^a   Kang, Huanrong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bevacizumab; Brain metastasis; NSCLC

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CARBOPLATIN; DIAMINOBENZIDINE; GEMCITABINE; IMMUNOGLOBULIN G ANTIBODY; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CA9 PROTEIN, HUMAN; TUMOR ANTIGEN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; SMOKING; BIOSYNTHESIS; BLOOD; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SECONDARY;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; CARBONIC ANHYDRASE IX; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84978646589     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947815Y.0000000045     Document Type: Article

References (30)

1. V.T.DeVitaJr, S.Hellman, S.A.Rosenberg, editors. Cancer: principles and practice of oncology. 6th edn. Philadelphia: Lippincott Williams; 2001; p. 2655–70.
2. W.R.Markesbery, W.H.Brooks, G.D.Gupta, A.B.Young. Treatment for patients with cerebral metastases. Arch Neurol. 1978;35:754–6.
3. S.Egawa, I.Tukiyama, Y.Akine, Y.Kajiura, S.Yanagawa, K.Watai, et al. Radiotherapy of brain metastases. Int J Radiat Oncol Biol Phys. 1986;12:1621–5.
4. J.Horton, D.H.Baxter, K.B.Olson. The management of metastases to the brain by irradiation and corticosteroids. AJR Am J Roentgenol. 1971;111:334–6.
5. L.S.Kim, S.Huang, W.Lu, D.C.Lev, J.E.Price. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis. 2004;21:107–18.
6. H.Bai, W.Z.He, B.H.Han. Relationship of the prognosis of lung cancer with brain metastases and the expressions of p53, nm23 and VEGF. China Oncol. 2007;17:774–8.
7. J.JuanYin, K.Tracy, L.Zhang, J.Munasinghe, E.Shapiro, A.Koretsky, et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis. 2009;26:403–14.
8. A.M.Jubb, A.Cesario, M.Ferguson, M.T.Congedo, K.C.Gatter, F.Lococo, et al. Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer. 2011;104:1877–81.
9. D.P.Kodack, E.Chung, H.Yamashita, J.Incio, A.M.Duyverman, Y.Song, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci USA. 2012;109:E3119–27.
10. E.J.Wuthrick, M.Kamrava, W.J.CurranJr, M.Werner-Wasik, K.A.Camphausen, T.Hyslop, et al. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer. 2011;117:5548–59.
11. D.Morgensztern, R.Govindan. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology. Clin Lung Cancer. 2008;9(Suppl 2):S57–S61.
12. M.Ilie, N.M.Mazure, V.Hofman, R.E.Ammadi, C.Ortholan, C.Bonnetaud, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer. 2012;102:627–35.
13. S.Heon, B.Y.Yeap, N.I.Lindeman, V.A.Joshi, M.Butaney, G.J.Britt, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18:4406–14.
14. B.Hemmerlein, A.Kugler, R.Ozisik, R.H.Ringert, H.J.Radzun, P.Thelen. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch. 2001;439:645–52.
15. J.Bennouna, J.Sastre, D.Arnold, P.Österlund, R.Greil, E.Van Cutsem, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
16. C.J.Allegra, G.Yothers, M.J.O'Connell, S.Sharif, N.J.Petrelli, S.H.Lopa, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31:359–64.
17. D.R.Spigel, P.M.Townley, D.M.Waterhouse, L.Fang, I.Adiguzel, J.E.Huang, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29:2215–22.
18. J.J.Vredenburgh, A.Desjardins, J.E.Herndon2nd, J.Marcello, D.A.Reardon, J.A.Quinn, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–9.
19. L.Gianni, G.H.Romieu, M.Lichinitser, S.V.Serrano, M.Mansutti, X.Pivot, et al. A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013;31(14):1719–25.
20. M.H.Cohen, J.Gootenberg, P.Keegan, et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12:713–8.
21. M.E.Gore, C.Szczylik, C.Porta, S.Bracarda, G.A.Bjarnason, S.Oudard, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757–63.
22. M.A.Socinski, C.J.Langer, J.E.Huang, M.M.Kolb, P.Compton, L.Wang, et al. Safety of bevacizumab in patients with nonsmall-cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255–61.
23. B.Besse, S.F.Lasserre, P.Compton, J.Huang, S.Augustus, U.P.Rohr. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16:269–78.
24. K.C.De Braganca, Y.Y.Janjigian, C.G.Azzoli, M.G.Kris, M.C.Pietanza, C.P.Nolan, et al. Efficacy and safety of bevacizumab in active brain metastases from nonsmall cell lung cancer. J Neurooncol. 2010;100:443–7.
25. M.Furuse, S.Kawabata, T.Kuroiwa, S.Miyatake. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol. 2011;102:471–5.
26. P.K.Jain. Normalizing tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
27. M.Mazzone, D.Dettori, R.Letite de Oliveira, S.Loges, T.Schmidt, B.Jonckx, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009;136:839–51.
28. A.Van Baardwijk, C.Dooms, R.J.van Suylen, E.Verbeken, M.Hochstenbag, C.Dehing-Oberije, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1 alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43:1392–8.
29. S.J.Kim, Z.N.Rabbani, M.W.Dewhirst, Z.Vujaskovic, R.T.Vollmer, E.G.Schreiber, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer. 2005;49:325–35.
30. Swinson DE, Cox G, O'Byrne KJ. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. British Journal of Cancer. 2004;91:1301–07